Home > Insider Trading > Filing (0001209191-23-047773)

Filing Details

Accession Number:: 0001209191-23-047773
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-08-30 18:02:07
Reporting Period:: 2023-08-28

Accepted Time:: 2023-08-30 18:02:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1807120	Design Therapeutics Inc.	DSGN	Pharmaceutical Preparations (2834)	823929248

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1848372	Arsani William	C/O Design Therapeutics, Inc. 6005 Hidden Valley Road, Suite 110 Carlsbad CA 92011		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-08-28	275,000	$2.15	1,040,000	No	4	P	Indirect	By Logos Global Master Fund LP
Common Stock	Acquisiton	2023-08-29	1,960,000	$2.44	3,000,000	No	4	P	Indirect	By Logos Global Master Fund LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Logos Global Master Fund LP
No	4	P	Indirect	By Logos Global Master Fund LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,217,627	Indirect	By Logos Opportunities Fund II, L.P.
Common Stock	814,874	Indirect	By Logos SPV 1 LP

Footnotes

The weighted average purchase price for the transaction was $2.15. The shares were purchased at a range of prices between $2.11 and $2.1677, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The weighted average purchase price for the transaction was $2.44. The shares were purchased at a range of prices between $2.29 and $2.50, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II") and Logos SPV 1 LP ("SPV 1"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. Logos Opportunities II GP LLC ("GP II") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.